Related Experiment Video
Updated: Aug 5, 2025
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Discovery of novel CDK2 inhibitors using multistage virtual screening and in vitro melanoma cell lines
Lihong Yang1, Mukuo Wang1, Beibei Li1,2
1State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Responses, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin, 300353, China.
Abstract:
Cyclin-dependent kinases 2 (CDK2) is a serine/threonine-protein kinase, which plays a key role in the regulation of cell cycle and is related to the occurrence and development of melanoma. In this study, we identified potent inhibitors for CDK2 by combining a multistage virtual screening strategy with bioassay validations. The biochemical activity of compounds was validated with ADP-Glo™ Kinase assay in vitro, and the results indicated that the biochemical activity of compound 1 (C1) was better than other selected compounds. Cell viability assay showed that the minimum inhibition concentration of C1 for CDK2 was lower than 4 μM. Further functional test results showed that C1 exerted significant antiproliferative, pro-apoptosis, and anti-migration activity in melanoma cell lines (A375 cells, WM35 cells, and A875 cells). Our findings suggested that the C1, virtually screened from compound libraries, as the novel inhibitor of CDK2, may be further developed as an effective therapeutic agent in the treatment of melanoma lines.
Insights
Researchers identified a novel inhibitor, compound 1 (C1), for cyclin-dependent kinases 2 (CDK2). This compound shows significant potential for treating melanoma by inhibiting cancer cell proliferation and migration.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Cyclin-dependent kinases 2 (CDK2) is a critical regulator of the cell cycle.
- CDK2 activity is implicated in the pathogenesis of melanoma.
- Targeting CDK2 presents a potential therapeutic strategy for melanoma treatment.
Purpose of the Study:
- To identify novel potent inhibitors of CDK2.
- To evaluate the therapeutic potential of identified inhibitors in melanoma.
- To validate the efficacy of a specific compound (C1) against melanoma cell lines.
Main Methods:
- A multistage virtual screening approach was employed to identify potential CDK2 inhibitors.
- Biochemical activity was validated using the ADP-Glo™ Kinase assay.
- In vitro assays included cell viability, antiproliferative, pro-apoptosis, and anti-migration assessments in melanoma cell lines (A375, WM35, A875).
Main Results:
- Compound 1 (C1) demonstrated superior biochemical activity compared to other screened compounds.
- C1 exhibited a low minimum inhibition concentration (< 4 μM) against CDK2.
- C1 displayed significant antiproliferative, pro-apoptotic, and anti-migratory effects in tested melanoma cell lines.
Conclusions:
- Compound 1 (C1) is a potent novel inhibitor of CDK2.
- C1 effectively inhibits key hallmarks of melanoma progression in vitro.
- C1 holds promise as a potential therapeutic agent for melanoma treatment.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...